While Praxis Precision Medicines Inc has underperformed by -9.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PRAX fell by -43.10%, with highs and lows ranging from $91.83 to $30.00, whereas the simple moving average fell by -53.41% in the last 200 days.
On March 03, 2025, H.C. Wainwright Reiterated Praxis Precision Medicines Inc (NASDAQ: PRAX) to Buy. A report published by Deutsche Bank on February 11, 2025, Initiated its previous ‘Buy’ rating for PRAX. Oppenheimer also rated PRAX shares as ‘Outperform’, setting a target price of $134 on the company’s shares in an initiating report dated August 05, 2024. Needham Initiated an Buy rating on June 24, 2024, and assigned a price target of $145. Guggenheim initiated its ‘Buy’ rating for PRAX, as published in its report on June 18, 2024. Robert W. Baird’s report from May 01, 2024 suggests a price prediction of $117 for PRAX shares, giving the stock a ‘Outperform’ rating. Truist also rated the stock as ‘Buy’.
Analysis of Praxis Precision Medicines Inc (PRAX)
Further, the quarter-over-quarter increase in sales is 1349.13%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Praxis Precision Medicines Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -70.98% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 10.77, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and PRAX is recording an average volume of 507.85K. On a monthly basis, the volatility of the stock is set at 8.44%, whereas on a weekly basis, it is put at 12.76%, with a loss of -20.27% over the past seven days. Furthermore, long-term investors anticipate a median target price of $99.27, showing growth from the present price of $28.60, which can serve as yet another indication of whether PRAX is worth investing in or should be passed over.
How Do You Analyze Praxis Precision Medicines Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 7.07%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 105.76% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
PRAX shares are owned by institutional investors to the tune of 105.76% at present.
